STOCK TITAN

Relay Therapeutics (RLAY) SEC Filings, Nov 2025-Jan 2026

RLAY NASDAQ

Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.

Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.

Rhea-AI Summary

Relay Therapeutics, Inc. reported that President and CEO Sanjiv Patel received a stock option grant. On January 13, 2026, he was awarded an option to buy 1,450,000 shares of Relay Therapeutics common stock at an exercise price of $7.94 per share. The filing states that the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, so long as he continues to serve with the company through each vesting date. Following this grant, he beneficially owned 1,450,000 derivative securities directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics reported that its Chief Financial Officer, Thomas Catinazzo, received a new stock option grant. On 01/13/2026, he was awarded a stock option to buy 400,000 shares of common stock at $7.94 per share. After this grant, he beneficially owns 400,000 derivative securities directly.

The option shares will vest in sixteen equal quarterly installments after January 13, 2026, and each installment requires his continued service with the company through the applicable vesting date. This filing records the award and resulting beneficial ownership rather than any share sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported both a share purchase and a sale of company stock. On December 31, 2025, he acquired 994 shares of common stock at $2.99 per share under the company’s 2020 Employee Stock Purchase Plan, a transaction described as exempt under Rule 16b-3 and voluntarily reported. On January 6, 2026, he sold 43,168 shares of common stock at $7.82 per share to cover income tax withholding obligations arising from the vesting of 136,854 restricted stock units on January 5, 2026, with no discretion over the sale terms.

After these transactions, he directly held 661,041 shares of common stock, which includes 136,854 shares underlying RSUs. The filing also reports 199,548 and 687,355 shares of common stock held indirectly in irrevocable family trusts with an independent trustee, for which Patel disclaims beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.20%
Tags
insider
Rhea-AI Summary

Relay Therapeutics (RLAY) reported an insider equity award. A company director disclosed a stock option grant to buy 207,931 shares at an exercise price of $6.86 per share on November 4, 2025.

The option expires on November 3, 2035 and vests in 36 equal monthly installments after November 4, 2025, contingent on continued service. The filing indicates direct ownership of the derivative security.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics (RLAY) disclosed a director stock option grant to purchase 207,931 shares at an exercise price of $6.86 per share on November 4, 2025.

The option vests in 36 equal monthly installments after November 4, 2025, conditioned on continued service. The option expires November 3, 2035, and the filing lists direct (D) ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics (RLAY) filed a Form 3 initial statement of beneficial ownership for a director. The filing reports that no securities are beneficially owned, as reflected in the remarks and supported by Exhibit 24 (Power of Attorney). The Date of Event Requiring Statement is 11/04/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
insider
Rhea-AI Summary

Relay Therapeutics (RLAY) filed an initial statement of beneficial ownership on Form 3 for a reporting person serving as a Director.

The filing states that no securities are beneficially owned. It indicates the form was filed by one reporting person and includes a power of attorney authorization. This is an administrative disclosure and does not report any transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics (RLAY) filed its Q3 2025 report, highlighting continued R&D progress and a stronger balance sheet cushion. The company reported a net loss of $74.1M for the quarter versus $88.1M a year ago, as operating expenses declined with research and development at $68.3M and general and administrative at $12.1M. Quarterly revenue was $0; year-to-date revenue was $8.4M, primarily from the Elevar agreement tied to lirafugratinib.

Cash and investments totaled $596.4M ($91.6M cash and equivalents; $504.9M investments) at September 30, 2025, and management states this can fund operations into 2029. Shares outstanding were 173,322,385 as of October 31, 2025. The Genentech collaboration for migoprotafib ended effective January 7, 2025. Relay advanced RLY‑2608, initiating the global Phase 3 ReDiscover‑2 trial in HR+/HER2‑ breast cancer and reported interim PFS signals in combination with fulvestrant. Lease actions reduced footprint, including a terminated 399 Binney lease and a new, smaller One Kendall Square office lease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
quarterly report
-
Rhea-AI Summary

Relay Therapeutics (RLAY) furnished a press release announcing financial results for the quarter ended September 30, 2025, and expanded its Board of Directors from seven to nine members.

The Board appointed Lonnel Coats (Class I, term expiring at the 2027 annual meeting) and Habib Dable (Class II, term expiring at the 2028 annual meeting), each determined independent under Nasdaq rules. Mr. Coats joined the Audit Committee and Mr. Dable joined the Nominating and Corporate Governance Committee. As non‑employee directors, each received an initial option to purchase 207,931 shares at an exercise price of $6.86 per share, vesting in equal monthly installments over 36 months. The company stated there are no related‑party transactions requiring disclosure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
current report
Rhea-AI Summary

Relay Therapeutics (RLAY) reported an insider transaction by its President and CEO (also a Director). On 11/03/2025, the executive sold 62,073 shares of common stock at $7 per share. The filing states this sale covered income tax withholding tied to the vesting of 136,853 RSUs on 10/31/2025, and the executive had no discretion over the sale.

After the transaction, the executive beneficially owned 703,215 shares directly, which includes 136,854 shares underlying RSUs. Additional holdings of 199,548 shares and 687,355 shares are held by irrevocable family trusts; beneficial ownership of those trust shares is disclaimed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
insider

FAQ

How many Relay Therapeutics (RLAY) SEC filings are available on StockTitan?

StockTitan tracks 114 SEC filings for Relay Therapeutics (RLAY), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Relay Therapeutics (RLAY)?

The most recent SEC filing for Relay Therapeutics (RLAY) was filed on November 20, 2026.